These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23139210)

  • 21. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
    Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
    Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Directed therapy of subtypes of triple-negative breast cancer.
    Carey LA
    Oncologist; 2011; 16 Suppl 1():71-8. PubMed ID: 21278443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
    Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
    Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
    Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
    Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
    Verma S; Bal A; Joshi K; Arora S; Singh G
    APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth.
    Sartorius CA; Harvell DM; Shen T; Horwitz KB
    Cancer Res; 2005 Nov; 65(21):9779-88. PubMed ID: 16266999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple-negative breast cancer: role of the androgen receptor.
    Gucalp A; Traina TA
    Cancer J; 2010; 16(1):62-5. PubMed ID: 20164692
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.